Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Rallies Behind Coronavirus Vaccines But Small Players May Have Best Shot

BravoVax CEO Sees Advantages For Nimble Firms

Executive Summary

Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.

You may also be interested in...



China Clears First Coronavirus Vaccine Trial

Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.

Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development

Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel